Pseudogene PRELID1P6 activates Akt/mammalian (or mechanistic) target of rapamycin (mTOR) pathway by increasing HNRNPH1-mediated TRF2 splicing and promoting glioma development [38]. The gene discussed is PRELID1P6; the disease is central nervous system cancer.